ArticleFrontiers in human neuroscience2026
Case Report: Beyond the monophasic myth: relapsing Baló's concentric sclerosis with residual disability.
Article in Frontiers in human neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Baló's concentric sclerosis (BCS) is a rare demyelinating disorder with a striking radiological signature. Its potential for relapse and the impact of vascular comorbidities on disease course remains underrecognized. Case presentation: A 52-year-old woman presented with acute limb weakness and sensory disturbances. MRI revealed pathognomonic concentric rings with concentric ring-like enhancement. Despite initial remarkable response to high-dose corticosteroids, she experienced a relapse at 10 months with new-onset limb tremor, persistent blood pressure fluctuations (on the basis of partial recovery) and lesion evolution on MRI. Repeat steroid therapy achieved disease stabilization, but residual motor disability persisted with a 1-year total follow-up (6 months of stable condition after relapse). Conclusion: This case highlights BCS's relapsing potential and the synergistic effect of uncontrolled hypertension on disease progression, challenging the notion of its uniformly monophasic course. Vigilant monitoring of vascular risk factors and personalized rehabilitation strategies are crucial, even after excellent initial recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.